DUPIXENT® (dupilumab injection) is indicated as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.

Request a Field Representative Visit

Connect with a DUPIXENT® Field Representative to get answers to any product-related questions you might have.

When systemic corticosteroids and/or surgery are not adequately controlling severe CRSwNP

DUPIXENT box and syringe.


The Freedom Support Program:

A program defined by the service we provide

Personalized support. Specialized care. Passionate team.


* Pre-filled pen available in 150 mg/mL (300 mg/2 mL) strength only. The DUPIXENT pre-filled pen is only for use in adults and adolescents aged 12 years and older. 
† Comparative clinical significance is unknown.

 

DUPIXENT (dupilumab injection) is indicated as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300229E
Last updated: 06/2023

paab logo